Riociguat significantly improves haemodynamics in patients with pulmonary hypertension with HFpEF: DYNAMIC Trial

EUROPE: According to a study published in the European Heart Journal, the vasodilator riociguat enhanced haemodynamics in patients with pulmonary hypertension and heart failure with preserved ejection fraction.
Riociguat was generally considered safe, however it did not alter clinical symptoms during the research period and caused more dropouts than a placebo, according to the authors.
Heart failure (HF) with preserved ejection fraction (HFpEF), which makes up roughly 50% of all instances of HF, is linked to poor quality of life (QoL), significant healthcare resource usage, and early mortality. Clinical heart failure with preserved ejection fraction is significantly made worse by the presence of pulmonary hypertension (PH) (HFpEF). Pulmonary vasodilators have not yet shown any promise as a treatment for heart failure.
In this trial, riociguat, an oral soluble guanylate cyclase activator, was used to treat PH-HFpEF patients over an extended period of time to investigate its efficacy.
For this objective, the PH-HFpEF was evaluated in the phase IIb, randomized, double-blind, placebo-controlled, parallel-group, multicenter DYNAMIC study. Five hospitals were chosen to recruit patients in Austria and Germany. Mean pulmonary artery pressure 25 mmHg, pulmonary arterial wedge pressure >15 mmHg, and left ventricular ejection fraction 50% were important eligibility criteria. Patients were randomly assigned to receive either a placebo or riociguat orally in 1:1 ratio. The dosage was increased for the patients from 0.5 mg TID to 1.5 mg TID. The right heart catheterization-measured change in cardiac output (CO) at rest from baseline to week 26 served as the primary efficacy outcome. On the entire analysis set, primary efficacy analyses were carried out. 56 patients received a placebo, while 58 patients received riociguat.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.